Thrombus Formation Initiation and Propagation

血栓形成起始和传播

• 批准号: 6814110
• 负责人: BARBARA C FURIE
• 金额: $ 42.5万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-02 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6814110
• 关键词: arterioles; cell surface receptors; coagulation factor IX; coagulation factor XI; collagen; glycoproteins; laboratory mouse; lasers; ligands; nuclear magnetic resonance spectroscopy; phosphatidylserines; platelets; selectins; thromboplastin; thrombosis

DESCRIPTION (provided by applicant): The objectives of this proposal are to determine the role of platelet collagen receptors and of factor XI in thrombus formation in vivo. While the role of these components of the hemostatic system have been well studied in vitro and mutations in some of the participating proteins in humans hint at in vivo roles, the opportunity now exists, using a unique real time intravital microscopy technique, to delineate their importance in vivo. The time course and kinetics of laser induced thrombus formation in the arterioles of mice glycoprotein VI null mice, mice with low levels of glycoprotein VI and mice lacking the integrin alpha2 beta1 will be examined to determine the role of these collagen receptors in thrombus formation in this model. The activation state of the platelets accumulating in thrombi in the three mouse genotypes will be examined to probe the role of the two different collagen receptors in platelet signaling in response to collagen. Both mice lacking glycoprotein VI and mice lacking the alpha2 integrin chain appear to be protected in mouse models of thrombosis but in contrast to the bleeding phenotype present in deficiency of glycoprotein Ib, another initiator of platelet adhesion at sites of injury, mice lacking glycoprotein VI or the alpha2 integrin chain do not bleed. Thus these proteins may be useful targets for anti-thrombotic agents warranting a better understanding of their role in thrombus formation in vivo. A current model for blood coagulation is that the initiation occurs through exposure of tissue factor at sites of vascular injury resulting in the generation of small quantities of factor Xa and thrombin. The amount of thrombin generated through this pathway is limited by the inhibition of the factor Vlla-tissue factor complex by TFPI, in the presence of factor Xa. The initial thrombin among other functions formed activates factor XI which then maintains the thrombin flux through activation of factor IX. The time course and kinetics of laser induced thrombus formation in factor XI null mice will be examined to obtain a better understanding of the role of factor XI in vivo. The elucidation of the molecular architecture of blood coagulation complexes remains one of the major unresolved problems in the understanding of this process. To complement our in vivo studies of the role of factor XI in thrombus formation the structure of the complex formed between the factor XI apple domain(s)and the factor IX Gla domain will be determined.

描述（由申请人提供）：本提案的目的是确定血小板胶原受体和因子XI在体内血栓形成中的作用。虽然这些止血系统成分的作用已经在体外得到了很好的研究，并且在人体中一些参与蛋白质的突变暗示了体内的作用，但现在有机会使用独特的实时活体显微镜技术来描绘它们在体内的重要性。我们将检测糖蛋白VI缺失小鼠、糖蛋白VI低水平小鼠和整合素α 2 β 1缺失小鼠的小动脉中激光诱导血栓形成的时间过程和动力学，以确定这些胶原受体在该模型中血栓形成中的作用。我们将检测这三种基因型小鼠血栓中血小板聚集的激活状态，以探讨两种不同的胶原受体在血小板对胶原反应的信号传导中的作用。在小鼠血栓模型中，缺乏糖蛋白VI和缺乏α 2整合素链的小鼠似乎都受到了保护，但与缺乏糖蛋白Ib（另一种损伤部位血小板粘附的引发剂）时出现的出血表型相反，缺乏糖蛋白VI或α 2整合素链的小鼠不会出血。因此，这些蛋白可能是抗血栓药物的有用靶点，从而更好地了解它们在体内血栓形成中的作用。目前的一种凝血模型是，通过暴露于血管损伤部位的组织因子，导致少量Xa因子和凝血酶的产生，从而发生凝血。在Xa因子存在的情况下，TFPI对vla -组织因子复合物的抑制限制了通过该途径产生凝血酶的量。在其他功能中形成的初始凝血酶激活因子XI，然后通过激活因子IX维持凝血酶通量。为了更好地了解因子XI在体内的作用，我们将研究激光诱导的因子XI缺失小鼠血栓形成的时间过程和动力学。血液凝固复合物的分子结构的阐明仍然是理解这一过程中未解决的主要问题之一。为了补充我们对因子XI在血栓形成中的作用的体内研究，将确定因子XI apple结构域和因子IX Gla结构域之间形成的复合物的结构。